CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 178 enrolled
Drug / intervention
Digoxin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03136068
NCT03136068Phase 4Completed
CompareCT.gov

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation: a Placebo-controlled, Double-blinded Randomized Controlled Trial

University of California, San Francisco·interventional·Posted May 2, 2017·Updated Oct 30, 2019

In Brief

A Phase 4 clinical trial evaluating Digoxin and Placebo for Abortion. Completed, enrolled 178 participants across 3 sites.

Detailed Summary

This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D\&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D\&E procedure, but doctors want to clarify how digoxin effects D\&E procedure time, if at all.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbortion
CountriesUnited States
CollaboratorsFPA Women's Health, Society of Family Planning, Oregon Health and Science University

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2, 2017
Enrollment StartFeb 23, 2017
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.2 years ago

Interventions

Digoxindrug

Trans-abdominal injection

Placebodrug

Trans-abdominal injection